logo
Lawsuit aims to stop enforcement of West Virginia's vaccine exemption order

Lawsuit aims to stop enforcement of West Virginia's vaccine exemption order

Yahoo23-05-2025

CHARLESTON, W.Va. (WBOY) — The American Civil Liberties Union of West Virginia (ACLU-WV) and Mountain State Justice (MSJ) have filed a lawsuit of behalf of parents to stop Gov. Patrick Morrisey's executive order allowing vaccine exemptions in schools.
The order, which was signed in January, directed health officials to stop enforcing 'compulsory school immunization requirements,' for students who request a religious exemption. A bill to codify religious exemptions failed in the state legislature.
The lawsuit filed in Kanawha County Circuit Court claims that Morrisey does not have the authority to enforce his order since the state legislature did not pass the bill.
'Governors do not rule by decree,' ACLU-WV Legal Director Aubrey Sparks said in a press release. 'At the center of this lawsuit is who gets to make these decisions for our students. On this question, the state Constitution is clear that the authority lies with the Legislature, not the governor.'
Bridge Sports Complex opens all-inclusive playground
The parents behind the lawsuit include those with children who are particularly susceptible to illness. Previously, students had to receive a medical exemption to attend school without being vaccinated for chickenpox, Hepatitis-B, measles, meningitis, mumps, diphtheria, polio, rubella, tetanus and whooping cough.
'Parents should be able to know their child will be safe when they send them off to school,' Sarah Brown, MSJ Executive Director, said in the press release. 'We are seeing the devastating effects of loosening vaccine requirements across the country, and that's why the Legislature wisely declined to loosen the restrictions here in West Virginia. It's vital that their decision not be undermined by the executive branch.'
The lawsuit asks for a judge to block the enforcement of Morrisey's order.
Morrisey said earlier this month that his stance on the order wasn't changed by the bill's failure or the several lawsuits that had been filed against it.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PBM lobby sues Arkansas over law requiring drug middlemen to sell pharmacies
PBM lobby sues Arkansas over law requiring drug middlemen to sell pharmacies

Yahoo

time7 hours ago

  • Yahoo

PBM lobby sues Arkansas over law requiring drug middlemen to sell pharmacies

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. The main lobby representing pharmacy benefit managers is suing Arkansas in a bid to stop the state's law preventing the drug middlemen from owning pharmacies. The Pharmaceutical Care Management Association's lawsuit filed Monday in a federal court argues that Arkansas' law — the first of its kind — is unconstitutional and would result in pharmacies closing and medications becoming more difficult for Arkansans to access. It's the latest legal challenge from the PBM industry as it hustles to halt the law and set a precedent that might dissuade other states from passing similar legislation. Arkansas' legislation, called Act 624, is meant to protect local community pharmacies from larger, more diversified chains by requiring companies that own both PBMs and pharmacies to shutter their operations in the state. When signing Act 624 in April, Gov. Sarah Huckabee Sanders said the law was necessary to curb anticompetitive behavior among major PBMs that threatens Arkansas' independent pharmacies. However, PBMs — powerful middlemen that shape interactions and payments between drugmakers, payers and pharmacies — decried the law, arguing it eliminates a significant source of efficiency in the pharmacy supply chain by forcing them to sell off their brick-and-mortar stores and halt mail-order pharmacy operations in the state. The policy would unfairly benefit Arkansas-owned pharmacies at their expense, major PBMs said. Now, the PCMA — which represents 20 PBMs, including the so-called 'Big Three' that control an outsized share of the market — is taking to the courts in an attempt to stop the law before it kicks in at the start of 2026. Arkansas' law will cause roughly 40 PBM-owned pharmacies to close, along with eliminating home delivery options and jeopardizing access to specialty drugs for patients managing complex conditions, according to the PCMA's complaint. Act 624 will also lead to job losses and reduce market competition, which could cause costs to to rise for patients and their payers, the association argues. 'We will continue to fight to protect patients' access to health care and educate policymakers and stakeholders about the severe consequences of harmful legislation threatening patient access to pharmacy services,' the PCMA said in an emailed statement. The lobby's lawsuit argues that Act 624 violates the Constitution's Dormant Commerce clause and Privileges and Immunities clause by penalizing out-of-state operators to protect local businesses. The law also violates the Bill of Attainder clause, which forbids states from enacting punishments — in this case, revoking an actor's permit to conduct business — without a court proceeding, according to the complaint. The complaint makes similar legal arguments as prior lawsuits filed against Arkansas' law by CVS and Cigna, which operate two of the largest PBMs in the country: Caremark and Express Scripts, respectively. 'PCMA does not bring this suit because Act 624 is bad policy, although it very certainly is. Rather PCMA brings this suit because Act 624 is as clear an example of unconstitutional state legislation as the Court is likely ever to see,' the complaint reads. The PCMA's suit, which was filed in Arkansas' eastern district against the state's pharmacy board, seeks a preliminary injunction barring enforcement of the law while the lawsuit proceeds. Navitus Health Solutions is also a plaintiff in the suit. The Wisconsin-based PBM, which operates on a pass-through model — meaning it makes money only through administrative fees and not by retaining rebates — is not a member of the PCMA. The outcome of the suits could have significant ramifications for the PBM industry, as other states considering similar legislation could be deterred or spurred on by the court's eventual decision. Bills with similar provisions were recently introduced in Vermont, Texas and New York. States are stepping into a gap left by Congress as lawmakers scramble to make prescription drugs more affordable. Despite numerous proposals to rein in controversial PBM business practices over the past few years — including a bill that would force PBMs to sell pharmacy businesses nationwide — Congress has yet to pass significant federal reform. However, lawmakers on both sides of the aisle in Washington have expressed anger over PBMs' business practices in recent hearings. And, the GOP megabill currently being considered by the Senate includes some PBM provisions, including banning spread pricing in Medicaid, preventing PBMs from being paid based on a drug's list price and requiring more transparency about PBMs' business practices. Recommended Reading CVS, Cigna sue Arkansas to overturn new PBM law

Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research
Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research

Business Wire

time13 hours ago

  • Business Wire

Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research

SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions. 'Our inclusion in this series reflects Novotech's commitment to supporting innovators with smarter, faster, and more regionally tailored clinical solutions,' said Tom Hickey, Director of Therapeutic Strategy. The Next Frontier explores how biotechnology is addressing some of the world's most urgent health and sustainability challenges. As part of the series, Novotech highlights its partnership with Tune Therapeutics in advancing a functional cure for Hepatitis B, a chronic disease impacting nearly 300 million people globally. As the global leader in Hepatitis clinical trials, Novotech brings deep therapeutic expertise and global execution capabilities to accelerate development and delivery for sponsors. Filmed in New Zealand with world-leading hepatologist Professor Edward Gane, where an estimated 100,000 people are living with Hepatitis B, the feature highlights Novotech's partnership model for supporting biotech and small to mid-size pharma sponsors. It demonstrates how Novotech accelerates clinical development through access to expert investigators, targeted patient populations, and efficient trial infrastructure across Asia-Pacific, Europe, and North America, while showcasing its global capabilities in infectious disease research and trial delivery. 'Our inclusion in this series reflects Novotech's commitment to supporting innovators with smarter, faster, and more regionally tailored clinical solutions,' said Tom Hickey, Director of Therapeutic Strategy. 'Hepatitis B remains a significant global health challenge, and our teams are proud to have such a long history contributing to meaningful progress in this area.' The series will officially launch at the BIO International Convention in Boston on June 16, 2025, and is now available globally via digital platforms at About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.

5 things to know for June 10: LA protests, Anti-ICE protests spread, Ukraine, Vaccines, Harvard
5 things to know for June 10: LA protests, Anti-ICE protests spread, Ukraine, Vaccines, Harvard

Yahoo

time13 hours ago

  • Yahoo

5 things to know for June 10: LA protests, Anti-ICE protests spread, Ukraine, Vaccines, Harvard

In an effort to boost birth rates, China is focusing on pain. Specifically, the excruciating agony of childbirth. While the practice of providing epidural anesthesia services to healthy pregnant women who are seeking pain relief during labor is widely utilized in many countries, only around 30% of pregnant women in China receive epidurals. To help promote a more 'friendly childbearing environment,' large hospitals in China must now offer this service. Smaller hospitals should be prepared to provide epidurals by 2027. Here's what else you need to know to Get Up to Speed and On with Your Day. The city is terrified, Los Angeles Mayor Karen Bass said. Not of crime or protests, but of ICE. 'I can't emphasize enough the level of fear and terror that is in Angelenos right now, not knowing if tomorrow or tonight it might be where they live, it might be their workplace, should you send your kids to school, should you go to work,' she said. Protesters are turning that fear into action, walking through city streets and standing in front of federal buildings to rail against the immigration crackdown. Local police have mobilized to keep the peace, but so have approximately 1,700 members of the National Guard who were deployed by President Donald Trump, not the state's governor. Last night, Trump ordered the deployment of another 2,000 National Guard members as well as a full Marine battalion based in Southern California. 'The level of escalation is completely unwarranted, uncalled for, and unprecedented — mobilizing the best in class branch of the US military against its own citizens,' California Gov. Gavin Newsom said. The LA protests, which began as a reaction to immigration raids, have sparked demonstrations around the country. Although about 150 demonstrators were arrested in San Francisco on Sunday, thousands more returned on Monday to march through the city's Civic Center and Mission neighborhoods. Similar protests took place in Atlanta, Boston, Dallas, New York, Pittsburgh, Seattle and Washington, DC. On Saturday, the nonviolent 50501 movement plans to hold 'No Kings' protests nationwide to encourage those in power to uphold the Constitution and to seek an end to executive overreach. Residents of Kyiv may have wanted to grab a few hours of sleep last night but finding such slumber was unlikely. Instead, the sky above Ukraine's capital filled with the sound of the air defense systems trying to stop incoming drones from causing more death and destruction. There were frequent explosions from the drones that got through the defenses and hours of blaring air raid sirens. Russia launched at least 315 drones at Ukraine overnight in what Ukrainian President Volodymyr Zelensky described as 'one of the largest attacks on Kyiv.' The assault damaged high-rise buildings, homes and cars in seven districts of the capital and injured at least four people. Russian drones also struck the southern port city of Odesa, killing at least two people and damaging a maternity ward. Health and Human Services Secretary Robert F. Kennedy Jr. dismissed the entire panel of vaccine advisers that guides the CDC on the vaccine schedule and required coverage of immunizations. In a Wall Street Journal op-ed, Kennedy said the group was plagued with conflicts of interest and will be replaced with new members. Each of the 17 members on the Advisory Committee on Immunization Practices typically are experts in the field who served in four-year cycles. Removing the entire panel prematurely was unprecedented. 'I've never seen anything this damaging to public health happen in my lifetime,' one just-dismissed panel member said. 'I'm shocked. It's pretty brazen. This will fundamentally destabilize vaccination in America.' The State Department has ordered US diplomatic posts around the world to 'resume processing' Harvard University student and exchange visitor visas. The new guidance was announced after a judge halted President Trump's latest attempt to block international students from attending the Ivy League school. In recent months, the Trump administration has demanded that Harvard change its hiring and admission requirements, eliminate diversity, equity, and inclusion programs, and alter rules for on-campus protests. But the school has resisted those orders and filed a lawsuit claiming the government's actions violate the First Amendment. On Monday, an amicus brief was submitted to the court that featured the signatures of more than 12,000 Harvard alumni in support of their alma mater. The White House did not respond to CNN's request for comment on the brief. Justin Baldoni's lawsuit dismissedA judge has dismissed the actor/director's $400 million defamation lawsuit against Blake Lively and Ryan Reynolds, alleging that the Hollywood couple sought to 'destroy' his career. Whole Foods' distributor hackedUnited Natural Foods, Inc., one of America's largest publicly traded health food wholesalers, has taken some of its systems offline after a massive cyberattack. Highlights from the red carpetWhat theatrical garb did Broadway's biggest names wear to the 2025 Tony Awards? Here are 13 fabulous looks. Talk about motivation!Wanna be in an Adam Sandler movie? Baltimore Ravens running back Derrick Henry may get the chance — if he rushes for more than 2,000 yards this year. Seeking a 'craveable kick'?Chipotle says that's the goal of its new dip, which combines classic ranch with adobo pepper. The condiment will be available in restaurants next week and will be offered for a limited time. Bestselling author Frederick Forsyth dies at 86The thriller writer penned more than 25 books, including 'The Day of the Jackal,' which was adapted into a film starring Edward Fox in 1973, and more recently a TV series starring Eddie Redmayne. 686,061That's how many babies were born in Japan in 2024. It's the first time the number of newborns fell below 700,000 since record-keeping began in 1899. 'Ending a $5 million research study when it is 80% complete does not save $1 million, it wastes $4 million.' — National Institutes of Health staffers, in a letter to their boss, Dr. Jay Bhattacharya, about what they see as the politicization of research and the destruction of scientific progress under the Trump administration. Check your local forecast here>>> Ready for the second coming?The film 'Dogma,' which was released in 1999, has returned to theaters. Director Kevin Smith says the movie about two fallen angels trying to get back into heaven plays better now than when it originally debuted.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store